Organisation paid for research Program year 2025 Source: CMS Open Payments

Arthritis Consultants Inc

Neither a doctor nor a teaching hospital

Research payments

$434,485

90 payments

Through program year 2025, Arthritis Consultants Inc is reported as receiving $434,485 in research payments, across 90 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $33,737 3
2024 Research $38,869 3
2023 Research $40,323 5
2022 Research $62,309 6
2021 Research $40,407 15
2020 Research $70,381 24
2019 Research $148,459 34

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ucb SA $166,765 11 payments
  2. Gilead Sciences, Inc. $128,286 35 payments
  3. Eli Lilly and Company $53,229 14 payments
  4. Janssen Research & Development, LLC $45,261 13 payments
  5. GlaxoSmithKline, LLC. $40,854 16 payments
  6. Amgen Inc. $90 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $87,242 3 payments
  2. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis $34,745 8 payments
  3. A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. $31,391 2 payments
  4. A Multicenter Long-Term Extension Study of 104 Weeks Including A Double Blind Placebo Controlled 40 Week Randomized Withdrawal Retreatment Period to Evaluate the Maintenance of Treatment Effect of Ixekizumab Ly2439821 in Patients With Axial Spondyloarthritis $26,452 2 payments
  5. A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $23,382 7 payments
  6. A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis $19,539 2 payments
  7. A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axia $17,979 1 payment
  8. A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $14,931 8 payments
  9. A Phase 3 Multicenter Study to Evaluate the Long Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis $14,819 4 payments
  10. A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $8,380 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record